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Post-stroke spasticityThe current practice in Germany and Austria, and the safety and efﬁcacy of botulinum toxin type A (BoNT-A;
Dysport) in the treatment of patients with post-stroke arm spasticity (with no ﬁxed upper-limb contractures),
were assessed in this observational prospective non-interventional study. One treatment cycle was documented
with assessments at baseline, approximatelyweek 4 (optional), and approximatelyweek12. Pattern of spasticity,
treatment goal, safety and efﬁcacywere recorded. Overall response and goal achievement was rated on a 4-point
scale (‘no goal achievement’, ‘goal achievement’, ‘good goal achievement’, ‘best goal achievement’). In total, 409
patients were included and 99% assigned to one of ﬁve arm-spasticity patterns. Therapy goals included reduced
muscle tone (92.6%), physiotherapy or occupational therapy support (63.8%), increased range of motion (61.8%),
pain reduction (58.9%), facilitation of care or hygiene (55.7%), and functional improvement (17.0%). Goals were
achieved in 84% of patients. The following factors had themost potential as predictors of treatment outcome: pre-
treatment; time since onset of spasticity; pattern of arm spasticity. Mean Dysport dosewas 728 U and an inverse
dose–response relationship was observed. Treatment was well tolerated. 500–1000 U was a safe and effective
treatment for post-stroke arm spasticity in this post-marketing evaluation.
© 2014 The Authors. Published by Elsevier B.V.Open access under CC BY-NC-ND license.1. Introduction
An ischemic or hemorrhagic stroke can cause damage to the brain
tissue and, if this occurs in the motor cortex or major motor pathways,
it can result in motor disorders. A typical syndrome arising from this
damage is the upper motor neuron syndrome (UMNS), including posi-
tive and negative features, one of which can be spasticity of the upper
and lower limb muscles. This often causes difﬁculties with activities of
daily living, creating a long-term need for treatment. Only 5% of stroke
patients with paresis and spasticity of the arm regain useful function,
and prospects of full recovery after 3 months are negligible [1]. Depend-
ing on the localization of the lesion, differentmuscle groups are affected
by stroke. Although stroke is one of themost common causes of spastic-
ity, other forms of brain injury can also result in spastic arm postures.ergstr. 12-24, 77709 Wolfach,
0.
).
. Open access under CC BY-NC-ND licThe combination of spastic muscles affected constrains the affected
arm in a speciﬁc posture or movement pattern, and ﬁve typical arm
spasticity patterns can be distinguished (Fig. 1) [2].
Of the numerous treatments that are currently available for post-
stroke upper limb spasticity, little functional beneﬁt has been demon-
strated [reviewed in 3]. Pharmacologic agents include those that act
on ion ﬂux in the central nervous system (CNS; e.g. baclofen, diazepam,
orphenadrine citrate) and musculature (e.g. dantrolene). However,
these compounds are relatively non-selective, commonly evoking rele-
vant adverse reactions in the absence of any signiﬁcant efﬁcacy [4,5].
Other pharmacologic agents includingmonoamines, drugs acting on ex-
citatory amino acids, cannabinoids, and neuromuscular blocking agents,
have not been shown to produce any signiﬁcant beneﬁts for patients [6].
Several alternative approaches that have shown inconsistent results
include injection of alcohol and phenol into motor nerve branches or
peripheral nerves [7], numerous physiotherapy techniques [reviewed
in 3], and procedures involving electrical stimulation ofmuscles and pe-
ripheral nerves [8].
Botulinum neurotoxin (BoNT) reduces muscle tone by selective-
ly targeting peripheral nerve endings. By selectively cleaving
synaptosomal-associated protein 25 (SNAP-25), BoNT type A (BoNT-A)ense.
Fig. 1. Five typical arm spasticity patterns.
87W.H. Jost et al. / Journal of the Neurological Sciences 337 (2014) 86–90inhibits release of the neurotransmitter acetylcholine at presynaptic
nerve endings [9]. As such, BoNT-A is established as an effective and
well-tolerated treatment for patients with post-stroke arm spasticity
[5,10], and treatment recommendations for BoNT-A with respect to tar-
get muscles and doses have been drawn up based on the ﬁve arm
spasticity patterns. There are currently three commercially available
preparations of type A toxins: Dysport® (abobotulinumtoxinA; Ipsen),
Botox® (onabotulinumtoxinA; Allergan Incorporated), and Xeomin®
(incobotulinumtoxinA; Merz Pharmaceuticals GmbH). Dysport is ap-
proved in Germany and Austria for the symptomatic treatment of
post-stroke arm spasticity in adults [11].
A prospective multi-center study was conducted to assess current
practice in Germany and Austria and to evaluate safety and efﬁcacy of
the treatment of patients with arm spasticity with Dysport. In this
study, response to treatment was assessed based on whether or not
patients met their goals of treatment assigned at baseline. Patient-
centered assessment is important for conditions such as spasticity,
where improvement in patient function and outcomes are the main
aims of treatment.
2. Methods
2.1. Study design and patients
This was a prospective open-label non-interventional multi-center
post-marketing surveillance study, conducted in 85 centers in Germany
and Austria. Male and female outpatients aged at least 18 years with
arm spasticity caused by apoplexia, scheduled to receive or already re-
ceiving treatment with BoNT-A were eligible for inclusion. Patients
were excluded if they hadﬁxed contractures at the upper limb or contra-
indications for Dysport therapy, as per the Summary of Product Charac-
teristics [11]; no further exclusion criteria were deﬁned.
2.2. Study treatment
All patients received a single injection treatmentwith Dysport to the
affected arm in accordance with the recommendations given in the
German or Austrian Summary of Product Characteristics. In addition,
the study protocol provided recommendations for Dysport dose and
muscle selection for each of the ﬁve typical arm spasticity patterns
(I to V; Fig. 1). Dosing, injection protocol, and target muscles were
based entirely on the judgment of the physician,whowere not required
to follow these pattern-speciﬁc recommendations. Control of injection
(palpation, electromyography [EMG], stimulation, or ultrasound) was
also at the physicians' discretion. Concomitant therapies were permit-
ted throughout the study e.g. physiotherapy or occupational therapy.
One treatment cycle was documented with assessments at baseline,an optional intermediate visit around week 4, and closing visit at ap-
proximately week 12.
2.3. Assessments
At baseline, patients and physicians selected one or several realistic
individual therapy goals for treatment from a list. These goals included
tone reduction, improvement of mobility, pain reduction, facilitation
of care/hygiene, support of physiotherapy and occupational therapy,
and individual functional gain. There were three options available to
the physician for assessing the achievement of the initially chosen ther-
apy goal: ‘fully achieved’, ‘partially achieved’, and ‘not achieved’, evalu-
ated at weeks 4 and 12.
Prior to data analysis, patients were classiﬁed into one of four groups
based on goal achievement status:
• ‘Goal Achieved’ (GA) group if no severe related adverse events (AEs)
were recorded and the therapy was deemed effective.
• ‘Good GA’ group if no severe related AEs were recorded, the therapy
was deemed effective, and 50% of the patient's treatment goals were
fully achieved.
• ‘Best GA’ group if no severe related AEs were recorded, the therapy
was deemed effective, and 100% of the patient's treatment goals
were fully achieved.
• If none of these criteria were met, the patient was as allocated to the
‘No GA’ group.
Any patient experiencing a severe related AE would be considered a
non-responder, regardless of response.
At the end of observation phase, 84% of patients achieved their pre-
deﬁned goals: 54% ‘GA’, 18% ‘GoodGA’, 12% ‘BestGA’. The remaining 16%
of patients were allocated to the ‘No GA’ group.
Physicians and patients were asked to assess the overall effec-
tiveness of the treatment at reducing symptoms on a 3-point
scale as ‘worse’, ‘no effect’, or ‘better’, and comment on how sat-
isﬁed they were with the treatment (‘very satisﬁed’, ‘satisﬁed’,
‘neither satisﬁed nor dissatisﬁed’, ‘dissatisﬁed’, or ‘very dissatis-
ﬁed’). AEs and data on patients discontinuing therapy were also
recorded.
2.4. Statistical analyses
Elementary descriptive statistical evaluation of all collected data
was performed using SAS 9.1 for Windows. Only patients who
attended all visits (initial visit, intermediate visit, and closing visit)
were included in the assessment evaluation of achieved therapy
goals. On the basis of this statistical analysis procedure, the predic-
tive variables with inﬂuence on the afﬁliation with a GA were to be
identiﬁed.
Table 1
Patient demographics and disease characteristics at baseline.
Characteristic (N = 406) Mean (SD)a
Age (n = 397), years 59.0 (12.8)
Male/female (n = 402), % 59.5/40.5
Cause of spasticity (n = 403), %
Cerebral bleeding 24.9
Cerebral ischemia 73.6
Other 5.2
Time between stroke and ﬁrst occurrence of spasticity
(n = 374), months
7.1 (26.8)
Duration of spasticity (from onset prior to clinic referral)
(n = 391), years
6.4 (8.6)
Form of spasticity (n = 404), %
One-sided 95.8
On both sides 3.7
Number of previous treatments (n = 202) 7.9 (8.1)
Previous treatments (n = 202), %
Dysport 70.8
Botox 26.2
Xeomin 3.0
NeuroBloc 1.0
No information available 1.0
Time since last botulinum toxin injection (n = 189), months 4.6 (5.3)
Number of patients cited for each characteristic are those for whom data were available.
a Unless otherwise stated.
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Fig. 2.MeanDysport dose (U) according to goal achievement at the end of the observation
phase. Error bars are SD. GA, goal achievement.
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tify factors inﬂuencing GA; this analysis was considered exploratory.
Most of the factors includedwere categorical factors, therefore a logistic
RA was used instead of linear RA. Independent factors included in the
model were:
• dose (three classes: b500, 500–1000, ≥1001 U);
• pre-treatment (yes or no);
• patterns (1, 3, 4, 2 and 5 pooled);
• gender;
• age (four classes:≤40 years, N40–60 years,N60–80 years, N80 years);
• BMI (three classes: ≤18.5 kg/m2, N18.5–25.0 kg/m2, N25.0 kg/m2);
• etiology;
• time since spasticity onset (three classes ≤2 years, N2–5 years,
N5 years);
• hemi- or diplegic;
• current concomitant therapy;
• number of goals (four classes: 1–2 goal(s), 3–4 goals, 5–6 goals, N6
goals);
• control of injection (any injection control technique additional to pal-
pation: EMG, ultrasound, stimulation); and
• whether the actual injection scheme per spasticity pattern conformed
to the recommended injection scheme.
For the stepwise regression analysis, only patients with documented
valid data for all predictive variables were included (n = 284; 70.0%).
Three different regression analyses were performed: GA; good GA;
best GA. No correlation or principal component analysis was
performed.
3. Results
3.1. Patient disposition and demographic characteristics
Eighty-ﬁve centers provided data for 409 patients. Three patients
were subsequently excluded from the analyses, due to missing data or
being under 18 years of age. Intermediate visits were attended by 317
patients, at approximately 4 weeks (mean 36.2 days), and 391 patients
attended the ﬁnal visit, at approximately 12 weeks post-treatment; the
mean time period of observation was 97.4 days. Complete attendance
to all study visits was achieved by 307 patients, whowere subsequently
included in the evaluation assessing achievement of therapy goals.
Dysport therapywas continued after completion of the study by 334 pa-
tients. The main reasons for not continuing Dysport treatment were:
persistent effect at time-point for re-treatment (43.6%), patient request
(25.6%), and missing effect (15.4%).
Patient demographics are summarized in Table 1. The median time
between stroke and spasticity was 7.1 months. BoNT-A injections had
previously been received by 50% of patients (mean, 7.9 cycles; range,
1 to 46). The majority of patients received concomitant therapy during
the treatment cycle: 93.8% (381/406) of patients received physiothera-
py and 56.4% (229/406) of patients received occupational therapy.
Twenty-nine percent (n = 119) received oral therapy for spasticity;
Baclofen was recorded in 45.4% of cases (54/119). Aside from oral ther-
apeutic agents for the treatment of further concomitant diseases, other
physical therapies such as massage, lymphatic drainage, water exercise
therapy, respiration therapy or logopedics were only rarely recorded,
6.2% (25/406) in total.
The therapy goals most frequently mentioned were reduced muscle
tone (92.6%), support of physiotherapy and occupational therapy
(63.8%), improvement ofmobility (61.8%), pain reduction (58.9%), facil-
itation of care or hygiene (55.7%), and improvement of functioning
(17.0%). The average number of goals per patient was 3.6.
Duration of spasticity, deﬁned by onset of spasticity prior to in-
clusion in this study, varied among patients categorized by GA,
with the longest duration reported for patients with best GA(mean 7.2 years) followed by GA or no GA (6.5 years), and good
GA (5.6 years).
3.2. Pattern distribution
Ninety-nine percent of the patients could be allocated to one of the
ﬁve pre-deﬁned typical arm spasticity patterns: 34% to pattern I, 36%
to pattern III and 23% to pattern IV, and 3% each to pattern II and V.
The majority of patients (77%) presented a spastic ﬂexed hand.
3.3. Treatment and dosing
The mean Dysport dose was 728 U (100–2300 U). In 73.6% of pa-
tients, a dose between 500 and 1000 U Dysport was injected, 16.9% of
patients received less than 500 U Dysport, and 9.5% received more
than 1000 UDysport. Themean dose of Dysport across theﬁve different
arm spasticity patterns was as follows: pattern I, 707 U; pattern II,
575 U; pattern III, 711 U; pattern IV, 799 U; and pattern V, 747 U.
An inverse relationship between dose and GAwas observed (Fig. 2).
Thus, the lowest average dose of Dysport (651 U) was administered to
the best GA group, with higher doses being used in those with good
GA (677 U), GA (733 U) and no GA (823 U).
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EMG (50.5%), stimulation (12.1%), and ultrasound (7.6%) [more than
onemethodmay have been used]. In 37.4% of cases, a technical method
wasused in conjunctionwith palpation. A positive relationship between
the use of palpation and an injection-guided technique (EMG, stimula-
tion or ultrasound) and GA was observed; the higher the GA, the larger
the percentage of patients with monitoring by at least one technical
method and palpation (best GA group, 62%; good GA group, 40%; GA
group, 37%; no GA, 17%).3.4. Efﬁcacy results
Overall, 84% (95%CI: 80–87%) of patients experienced a degree of GA
(best GA, good GA, or GA)with Dysport therapy (Fig. 3). The percentage
of patients with ‘GA’ was broadly similar between the spasticity
patterns.
Themajority of patients also assessed their situation as ‘better’ at the
intermediate visit (89.0%; 282/317) and closing visit (87.2%; 341/391).
A total of 87.0% of patients were ‘satisﬁed’ with the Dysport treatment,
with only 8.7% being ‘dissatisﬁed’. The dissatisfactionwas predominant-
ly attributed to the lack of beneﬁt from treatment.
A large percentage of the physicians documented improvement dur-
ing the intermediate visit (94.6%; 300/317), as well as the closing visit
(91.3%; 357/391). In 86.7% (339/391) of cases, the physicians were
very or rather satisﬁed with the Dysport therapy. A few physicians
were neither satisﬁed nor dissatisﬁed (5.4%) or expressed dissatisfac-
tion with treatment (3.1%). Dissatisfaction was predominantly attribut-
ed to a missing effect of the therapy.
The goals of treatment determined at the ﬁrst visit were fully or
partially achieved in the majority of patients: the therapy goal of pain
reduction was achieved in 94.7% of patients, tone reduction was
achieved in 94.3%, improvement in administering physio- or occupa-
tional therapy was achieved in 93.0%, facilitation of care/hygiene was
improved in 89.9%, and improvement in arm mobility was achieved
in 89.2%.
In the SLRA based on GA, the four most inﬂuential factors of a posi-
tive GA were pre-treatment (whether the patients were de novo or
had been previously treated with BoNT-A), time since spasticity onset,
the spasticity pattern, and overall injection dose. Factors signiﬁcantly
predictive of good GA were patient status (pre-treated vs. naïve)
(p b 0.01) and duration of spasticity (p = 0.03). Pattern of spasticity
(p = 0.06), etiology of spasticity (p = 0.08), number of therapy goals10%
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Fig. 3. Goal achievement at the end of the ob(p = 0.12), and cumulative injection dose (p = 0.15) did not reach sig-
niﬁcance in the “Good GA” regression analysis.
3.5. Safety
A total of seven AEs were reported in 6/409 patients (1.5%); onewas
serious (sepsis) but not related to Dysport treatment. AEs related to
therapy included weakness in the injected arm/hand (n = 3) and pto-
sis (n = 1), both of which can be regarded as expected due to the
known effects of botulinum toxin. Edema (n = 1) and seizures
(n = 1) were also reported and were assessed as not related to treat-
mentwith Dysport. Treatmentwas discontinued in two patients follow-
ing an AE (arm weakness, n = 1; loss of remaining function, n = 1;
neither were serious).
4. Discussion
This non-interventional study assessed the efﬁcacy and safety of
Dysport for the treatment of post-stroke arm spasticity. Dysport proved
to be both effective and well tolerated. Response to Dysport was also
rapid,withmany patients experiencing improvement by the intermedi-
ate visit. Both physicians and patients rated the treatment as having a
good effect. In addition to the high number of patients responding to
treatment, Dysport administration resulted in a high number of patients
achieving treatment goals set at baseline, demonstrating that improve-
ments in spasticity translate into meaningful improvement in patient-
centered outcomes. Thus, these data show that Dysport meets the ex-
pectations of treatment in a vast majority of patients suffering from
arm spasticity. A very low rate of AEs and discontinuation were report-
ed, supporting the good safety proﬁle of Dysport. Observed related AEs
were expected based on the known effects of BoNT-A [12].
Given the patient population, it was not surprising that reduction in
muscle tonewas identiﬁed as themain goal of treatment in themajority
of patients. Other important goals set by more than 50% of patients in-
cluded improvement in administering physio- or occupational therapy,
improvement of mobility, pain reduction, and facilitation of care or hy-
giene. Importantly, these goals were achieved in the majority of pa-
tients. Although functional improvement was speciﬁed as a treatment
goal only in the minority of patients, this would be expected given the
chronic nature of spasticity in this population; improvements in active
function is a more common goal in the early stages of treatment,
while improvement in passive function is more common in chronic12%
18%
73%
54%
27%
16%
V Pattern V
(n=15)
Overall
(n=406)
No goal achievement
Goal achievement
Good goal achievement
Best goal achievement
servation phase, overall and by pattern.
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hygiene [13].
This study shows dosages between 500 and 1000 U of Dysport for
the treatment of arm spasticity seem to be adequate and well tolerated,
in agreement with both controlled studies [14,15] and data from retro-
spective analysis of long-term use [16]. The results of this study suggest
that spasticity pattern II is treatedwith lower doses in clinical practice. It
should be noted that an inverse relationship between dose and GA was
observed in this study. There are several possible explanations for this
observation. For example, lower doses may have permitted some de-
gree of residual muscle tone for compensatory movement, thus leading
to improved patient satisfaction. It is also possible that those with best
GAmay be familiar with the effects of treatment allowingmore realistic
prediction of outcomes, regardless of dose. It also cannot be ruled out
that use of goal attainment to assess response to treatment is prone to
error, resulting in this unexpected ﬁnding. Alternatively, other factors
not included in the list of independent factors as severity of spasticity,
may have inﬂuenced the ﬁndings. For example, patients receiving
higher doses may have hadmore severe spasticity, whichmay have de-
creased the chance of functional improvement, despite administration
of higher doses. Although the reasons for this ﬁnding are unclear, it is
important to highlight that patients beneﬁtted from treatment and
use of patient-centered goals remains an important method of evaluat-
ing treatment outcomes for patients and clinicians.
In addition to conﬁrming reports demonstrating clinical efﬁcacy of
Dysport in this indication, this study shows that current Dysport dosing
used in clinical practice leads to a high level of patient and physician sat-
isfaction with treatment. It should be noted that while dosing recom-
mendations based on spasticity pattern were provided to clinicians, it
is not known how closely physicians adhered to these guidelines, and
this should be considered when interpreting the ﬁndings.
Exploratory analysis to identify potential factors associated with GA
demonstrated that several patient factors (e.g. previous treatment sta-
tus, duration of spasticity) were important in determining outcome. Im-
portantly, factors under clinicians' control, namely total injection dose
and injection control techniques, were potential predictors of outcome.
This emphasizes the importance of arm pattern classiﬁcation and corre-
sponding treatment recommendation for guiding decisions on BoNT-A
treatment in patients with arm spasticity. Arm pattern classiﬁcation
also provides common terminology and facilitates a quick and under-
standable information exchange with other physicians. The ﬁndings of
this study indicate that the dose of Dysport administered is dependent
on the arm spasticity pattern and may provide future guidance to
physicians.
5. Conclusion
In conclusion, Dysport proved to be a safe and effective treatment for
post-stroke arm spasticity in this post-marketing evaluation.Conﬂicts of interest and source of funding
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